NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Joe Biden
    United States of America
    COVID-19
    Russia-Ukraine crisis
    NewsBytes
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / World News / UK approves Pfizer-BioNTech's COVID-19 vaccine; first doses expected next week
    World

    UK approves Pfizer-BioNTech's COVID-19 vaccine; first doses expected next week

    UK approves Pfizer-BioNTech's COVID-19 vaccine; first doses expected next week
    Written by Siddhant Pandey
    Dec 02, 2020, 02:18 pm 3 min read
    UK approves Pfizer-BioNTech's COVID-19 vaccine; first doses expected next week

    The United Kingdom on Wednesday gave emergency approval to Pfizer and BioNTech's COVID-19 vaccine, becoming the first Western country to allow mass immunization against the viral disease. The vaccine, which has been shown to have 95% efficacy in late-stage clinical trials, will be made available across the country for at-risk groups starting next week. The UK has pre-ordered 40 million doses of the vaccine.

    Vaccine meets 'strict standards of safety, quality, effectiveness'

    The vaccine has been given emergency approval by the Medicines and Healthcare Products Regulatory Authority (MHRA). Experts at MHRA concluded that the vaccine has met "strict standards of safety, quality, and effectiveness," a Department of Health and Social Care spokesperson was quoted as saying by The Guardian. Russia and China have already approved vaccines, albeit without the results of large-scale efficacy tests.

    'Panel to publish advice for priority groups to receive vaccine'

    The spokesperson added, "The joint committee on vaccination and immunization will shortly also publish its latest advice for the priority groups to receive the vaccine, including care home residents, health and care staff, the elderly and the clinically extremely vulnerable."

    10 million doses to arrive this year: Health Secretary

    The delivery of the 40 million doses will start immediately. Health Secretary Matt Hancock said he expects 10 million doses to arrive this year. Care home residents are first in line to receive the vaccine, followed by people aged over 80 and the National Health Service staff. Pfizer and BioNTech said they can supply 50 million doses in 2020 and 1.3 billion by 2021-end.

    US, Europe to approve vaccine within weeks

    The United States, which has pre-ordered 100 million doses, and Europe, which has bought 200 million, are also expected to approve the vaccine within weeks. The UK's approval of the vaccine before the US—particularly one developed by an American company—is set to put pressure on US regulators. Notably, the MHRA has approved the vaccine within just a week, which is unprecedented.

    Vaccine uses mRNA technology; 95% effective

    Another first attached to the Pfizer-BioNTech's vaccine is that the messenger RNA (mRNA) technology it uses has never been used for an approved vaccine. Late-stage trial data found the vaccine has 95% efficacy and was equally effective among younger and older volunteers. The vaccine has to be kept at low temperatures of -70°C, which is a challenge for its delivery.

    Vaccine will help reduce hospitalizations among high-risk groups: BioNTech co-founder

    Ugur Sahin, the CEO and co-founder of BioNTech, said in a statement, "The emergency use authorization in the UK will mark the first time citizens outside of the trials will have the opportunity to be immunized against COVID-19." He added, "We believe that the rollout of the vaccination program in the UK will reduce the number of people in the high-risk population being hospitalized."

    'Historic moment in fight against COVID-19'

    "Today's emergency use authorization in the UK marks a historic moment in the fight against COVID-19," Pfizer CEO Albert Bourla said, "We are focused on moving with the same level of urgency to safely supply a high-quality vaccine around the world."

    Share this timeline
    Facebook
    Whatsapp
    Twitter
    Linkedin
    Pfizer
    Europe
    United Kingdom
    Matt Hancock

    Pfizer

    Will being exposed to low quantities of coronavirus generate immunity? Coronavirus
    Deliveries of Pfizer-BioNTech's coronavirus vaccine could start before Christmas Coronavirus
    Pfizer's COVID-19 vaccine '95% effective'; to seek emergency US authorization NITI Aayog
    Days after upsetting results, Trump comes close to conceding defeat Donald Trump

    Europe

    Nokia Smart TV 75-inch launched in Europe Google
    Moto G 5G is launching in India on November 30 Motorola
    Moto E7, with MediaTek Helio G25 chipset, launched Ram (Random Access Memory)
    Moto G9 Power, G 5G to be launched in December Motorola

    United Kingdom

    Coronavirus: UK government extends work visas for Indian, foreign doctors Priti Patel
    The Queen and Prince Philip mark 73rd wedding anniversary England
    Ford EcoSport Active SUV breaks cover: Details here Apple
    Citing COVID-19, China restricts entry of foreign nationals from India Ministry of Health and Family Welfare

    Matt Hancock

    Coronavirus: UK Prime Minister Boris Johnson moved to intensive care Boris Johnson
    COVID-19 vaccine: 90-year-old woman receives first Pfizer shot in UK Pfizer
    UK claims South Africa's COVID variant more dangerous, latter rejects South Africa
    UK study shows COVID-19 infections have fallen significantly in England England

    Love World News?

    Subscribe to stay updated.

    World Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023